×
About 1,575 results

ALLMedicine™ Mean Corpuscular Volume Center

Research & Reviews  542 results

Erythropoietic effects of vadadustat in patients with anemia associated with chronic ki...
https://doi.org/10.1002/ajh.26644
American Journal of Hematology; Koury MJ, Agarwal R et. al.

Jun 26th, 2022 - Patients with chronic kidney disease develop anemia largely because of inappropriately low erythropoietin production and insufficient iron available to erythroid precursors. In four phase 3, randomized, open-label, clinical trials in dialysis-depe...

Treatment of Hemochromatosis
https://clinicaltrials.gov/ct2/show/NCT00007150

Jun 24th, 2022 - Hereditary hemochromatosis (HH) occurs in 1 in every 200-250 individuals of northern European descent, and is the most common inherited disease in this population. Although the molecular pathophysiology remains incompletely understood, a homozygou...

Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)-Exploring Its Possible Cli...
https://doi.org/10.3390/curroncol29060330
Current Oncology (Toronto, Ont.); Rihacek M, Selingerova I et. al.

Jun 24th, 2022 - Sunitinib is a broad-spectrum multitargeted tyrosine kinase inhibitor mainly used as second-line therapy for non-resectable gastrointestinal stromal or first-line treatment option of metastatic renal cell carcinoma (mRCC), and as an "off-label" op...

Identifying metabolic parameters related to severity and extent of periodontitis in dow...
https://doi.org/10.1111/jre.13028
Journal of Periodontal Research; Mouchrek MMM, Franco MM et. al.

Jun 23rd, 2022 - Systemic metabolic status and periodontitis can be related in patients with Down syndrome (DS). The objective of this study was to identify metabolic indicators (anthropometric measurements, blood pressure, and serum markers) related to severity a...

Application of the Fluorescence Method on Sysmex XN9000 Hematology Analyzer for Correct...
https://doi.org/10.1093/labmed/lmac063
Laboratory Medicine; Deng J, Xie S et. al.

Jun 18th, 2022 - Although small red blood cells are a well-known analytical pitfall that could cause artifactual increase of the platelet count, limited information is available on the accuracy of impedance platelet counting in cases with microcytosis. The aim of ...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  21 results

Treatment of Hemochromatosis
https://clinicaltrials.gov/ct2/show/NCT00007150

Jun 24th, 2022 - Hereditary hemochromatosis (HH) occurs in 1 in every 200-250 individuals of northern European descent, and is the most common inherited disease in this population. Although the molecular pathophysiology remains incompletely understood, a homozygou...

Determinants of Neonatal Anemia in Women Carrying Multiples
https://clinicaltrials.gov/ct2/show/NCT01582802

Mar 25th, 2022 - Pregnant women (n=100-125) carrying multiples (twins and triplets) will be identified when entering prenatal care. Women will be invited to participate in a longitudinal study of Fe homeostasis across pregnancy and at delivery in the maternal / ne...

Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa
https://clinicaltrials.gov/ct2/show/NCT02675790

Jan 19th, 2022 - Sub-Saharan Africans are disproportionately affected with sickle cell disease (SCD). In the most populous country in sub-Saharan Africa, Nigeria, over 150,000 children with the most severe form of SCD, sickle cell anemia (SCA), are born per year a...

Haemoglobin Concentration on COVID-19
https://clinicaltrials.gov/ct2/show/NCT04377607

Sep 16th, 2020 - In late December 2019, cases of pneumonia of unknown etiology began to appear in Wuhan, Hubei, China. This disease, which was named COVID-19 by the World Health Organization (WHO) on February 11, 2020, was identified as serious acute respiratory s...

Music Therapy in Sickle Cell Transition Study
https://clinicaltrials.gov/ct2/show/NCT02466555

Sep 13th, 2019 - The purpose of this study is to investigate the effects of the BEATS Music Therapy Program on the self-efficacy, trust, knowledge, and adherence of young adult patients with sickle cell disease during transition. Primary Hypotheses: Compared to ba...

see more →

News  66 results

Clinical Presentation of Subacute Combined Degeneration in a Patient With Chronic B12 Deficiency
https://www.mdedge.com/fedprac/article/252920/neurology/clinical-presentation-subacute-combined-degeneration-patient
Nathan Kostick, Evan Chen et. al.

Mar 21st, 2022 - Subacute combined degeneration (SCD) is an acquired neurologic complication of vitamin B12 (cobalamin) or, rarely, vitamin B9 (folate) deficiency. SCD is characterized by progressive demyelination of the dorsal and lateral spinal cord, resulting i.

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment
https://www.onclive.com/view/advanced-systemic-mastocytosis-expert-insight-into-epidemiology-diagnosis-and-treatment

Sep 15th, 2021 - SYSTEMIC MASTOCYTOSIS (SM) is a rare disease that often first presents on the skin. It is characterized by the overaccumulation of mast cells (MCs), which can then penetrate such internal organs as bone marrow (BM).¹ Challenges in identification a...

Does optimal iron absorption include vitamin C?
https://www.mdedge.com/internalmedicine/article/242911/womens-health/does-optimal-iron-absorption-include-vitamin-c
Douglas S. Paauw, MD

Jul 14th, 2021 - A 46-year-old woman presents with fatigue. She reports that she has had unusually heavy periods for the past 6 months.

Diverse Set of Biomarkers Tied to Increased MDD Incidence
https://www.medscape.com/viewarticle/954678

Jul 13th, 2021 - Takeaway In a large community-based cohort study, biological markers of liver, kidney and endocrine dysfunction, innate immunity, anaemia and macrocytosis were associated with an increased 5-year incidence of major depressive disorder (MDD). Why t...

FDA Grants Breakthrough Therapy Designation to Rusfertide for Polycythemia Vera
https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-rusfertide-for-polycythemia-vera

Jun 4th, 2021 - The FDA has granted breakthrough therapy designation to rusfertide (PTG-300) as a potential therapeutic option for patients with polycythemia vera to reduce erythrocytosis in those who do not require further treatment for thrombocytosis and/or leu...

see more →